PhorMed

PhorMed is developing a drug with the potential to treat several life-threatening diseases — from cancer to Parkinson’s to acute respiratory issues.

The company’s drug is called RP-323. Its job is to repair damaged and mutated cells while killing cancerous cells at the same time. PhorMed is in clinical trials for this drug, where the company has already achieved successful results in a Phase I study for safety.

Given its drug’s potential, PhorMed is targeting a total market valued at close to twenty-five billion dollars.

Team Background

McCoy Moretz - CEO and Treasurer

Richard Chang - Inventor

Co-Investors